YS Biopharma Granted Patent In The U.S. For Immunotherapy Targeting Chronic Hepatitis B Virus Infection
Portfolio Pulse from Benzinga Newsdesk
YS Biopharma Co., Ltd. (NASDAQ:YS) has been granted a patent by the United States Patent and Trademark Office for its immunotherapeutic vaccine, PIKA YS-HBV-002, designed to treat chronic hepatitis B virus infection. The company plans to submit an Investigational New Drug application and start clinical development of the vaccine in 2024.
September 15, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
YS Biopharma has been granted a patent for its hepatitis B immunotherapy, which could potentially provide a new revenue stream once it enters the market. However, clinical development is not expected to start until 2024.
The granting of a patent is a positive development for YS Biopharma as it provides the company with exclusive rights to develop and sell the immunotherapy. This could potentially lead to increased revenues in the future. However, as clinical development is not expected to start until 2024, the impact on the company's financials will not be immediate.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100